Ancillary OON denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for ancillary oon are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied This Out-of-Network Ancillary Service as Experimental

Aetna's "experimental or investigational" denial means the plan concluded that the out-of-network ancillary service lacks sufficient evidence of clinical effectiveness to meet Aetna's coverage standard. This category commonly affects newer rehabilitation modalities, specialized infusion protocols, advanced wound care techniques, or diagnostic procedures not yet widely adopted in-network.

This is one of the most commonly overturned denial types on external review. Insurers apply their own internal evidence standards, which may lag behind the consensus of treating clinicians and relevant professional societies.

## Federal Appeal Rights

• Internal appeal: Submit within 180 days of the denial. Include peer-reviewed literature and a clinician statement. Aetna must respond within the ACA-mandated timeframe (30 days pre-service; 60 days post-service).
• External review (ACA §2719): Experimental/investigational denials are explicitly eligible for IRO review. The IRO applies an independent evidence standard, not Aetna's internal policy. Request external review within approximately 4 months of your final internal denial.
• Expedited track: Available if delay creates serious risk of harm; decisions required within 72 hours.
• ERISA §503: Employer-plan members are entitled to full-and-fair review with access to all documents, guidelines, and criteria used in the denial.

## Documents to Gather

1. Diagnosis and clinical context — full chart notes establishing the diagnosis and the clinical rationale for choosing this specific ancillary service. 2. Prescriber medical-necessity letter — a detailed statement from the ordering clinician explaining why the service is appropriate, citing guideline support from the applicable professional organization (e.g., the relevant specialty society) without relying on internal trial data. 3. Peer-reviewed literature — published studies, systematic reviews, or technology assessments supporting the service's clinical validity; focus on evidence that appears in recognized databases. 4. Guideline organization statements — published position statements from the relevant specialty society or national guideline body recognizing the service as a standard or accepted option. 5. Aetna's Clinical Policy Bulletin — obtain the specific CPB cited in the denial; review the evidence table Aetna used and identify any literature it omitted. 6. Failed or inadequate in-network alternatives — documentation that conventional in-network options were tried and did not achieve the clinical goal.

## Criteria-Mapping Structure

List every element of Aetna's experimental-status test from the applicable CPB. For each element — such as FDA clearance status, peer-reviewed evidence, or professional society acceptance — provide the corresponding supporting document from your file. If Aetna's policy cites specific evidence categories, show that your submitted literature meets or exceeds them.

## Practical Next Step

Aetna is required to provide you, free of charge, the clinical criteria, guidelines, and any expert opinion it used to classify the service as experimental. Request these before drafting your appeal so you can address each factor directly.